DCOY
Decoy Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.17
+0.00%Sep 29, 2026, 11:30 UTC
Decoy Therapeutics reported preclinical pharmacokinetic data showing that a single intranasal dose of its DCOY-CoV program candidate sustains drug levels above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue.
Source:Sep 23, 2026, 21:07 UTC
Decoy Therapeutics Inc. entered a warrant inducement agreement under which a holder exercised 1,184,434 Series B Milestone Warrants at a reduced price of $3.25 per share for gross proceeds of about $3.85 million, and the company issued new unregistered warrants to purchase up to 2,368,868 shares at $3.25 per share.
Sep 22, 2026, 11:30 UTC
Decoy Therapeutics announced a refined corporate strategy to explore a pan-filovirus program using its D-MAVs candidates along the FDA Animal Rule pathway for expedited regulatory approval.
Source:Jun 27, 2026, 00:11 UTC
Decoy Therapeutics entered into a securities purchase agreement for a private placement financing expected to provide approximately $3.5 million in gross proceeds.
Source: